In simple words: This code indicates that the patient is currently taking medication that affects their bone marrow function, impacting blood cell production, and this use is long-term.

This code indicates the ongoing use of a myelosuppressive agent for an extended period. Myelosuppressive agents are medications that suppress the bone marrow's function, reducing the production of blood cells.

Example 1: A patient with chronic myelogenous leukemia is receiving long-term treatment with hydroxyurea, a myelosuppressive agent, to control the disease., A patient with polycythemia vera is prescribed long-term ruxolitinib, a myelosuppressive agent, to manage their condition., A patient with essential thrombocythemia is undergoing long-term anagrelide therapy, which is myelosuppressive, to reduce the risk of blood clots.

The documentation should include the specific myelosuppressive agent being used, the underlying condition being treated, the duration of therapy, and any monitoring results related to blood cell counts and other potential side effects.

** This code should not be used for patients receiving short-term or temporary myelosuppressive therapy. Refer to other appropriate Z codes if the drug therapy is short-term rather than long-term. Ensure any underlying conditions, such as anemia, leukopenia, or thrombocytopenia, are also coded as applicable.